Virus therapy takes on bladder cancer in early trial
NCT ID NCT07359235
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a modified virus called KD01, given directly into the bladder, to see if it is safe and can fight bladder cancer. The study includes 29 patients with either high-risk non-muscle-invasive bladder cancer or muscle-invasive bladder cancer. Some patients also receive an immunotherapy drug called AK104. The goal is to find the right dose and check for side effects and tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KD01 (a modified virus that targets and kills cancer cells) and AK104 (an immunotherapy drug) in some patients
What this could lead to
If successful, this could point toward a new treatment option for bladder cancer that uses a virus to attack tumors directly.
What could go wrong
This is a very early Phase 1 trial with only 29 participants, so safety and effectiveness are not yet proven. The virus may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON MUSCLE INVASIVE BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430074, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact